Breast Cancer Therapeutics

Breast Cancer Therapeutics


Global Breast Cancer Therapeutics Market to Reach US$90.4 Billion by 2030

The global market for Breast Cancer Therapeutics estimated at US$40.2 Billion in the year 2023, is expected to reach US$90.4 Billion by 2030, growing at a CAGR of 12.3% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$74.9 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 11.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.4 Billion While China is Forecast to Grow at 16.1% CAGR

The Breast Cancer Therapeutics market in the U.S. is estimated at US$10.4 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$21.9 Billion by the year 2030 trailing a CAGR of 16.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.2% and 10.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.2% CAGR.

Global Breast Cancer Therapeutics Market - Key Trends & Drivers Summarized

What Constitutes Modern Breast Cancer Therapeutics and Their Impact on Treatment?
Breast cancer therapeutics encompass a wide range of medical treatments designed to target and eliminate breast cancer cells. These treatments include hormonal therapies, chemotherapy, targeted therapy, and increasingly, immunotherapy. Hormonal therapies target hormone-receptor-positive breast cancers by blocking the body’s ability to produce hormones or by interfering with the effects of hormones on breast cancer cells. Chemotherapy remains a cornerstone treatment, used either before surgery (neoadjuvant therapy) to shrink tumors or after (adjuvant therapy) to destroy any remaining cancerous cells. Targeted therapies and immunotherapies represent a newer class of drugs that specifically target molecular pathways associated with breast cancer growth and spread. The evolution of these treatments has significantly improved survival rates and quality of life for breast cancer patients, making personalized medicine an achievable goal in oncology.

How Are Technological Advancements Influencing Breast Cancer Treatment?
Technological advancements are drastically reshaping the landscape of breast cancer treatment. The development of genomic testing technologies, for example, allows for more precise identification of individual cancer characteristics, guiding the selection of therapies that are most likely to be effective for each patient. This approach, known as precision medicine, tailors treatment to individual genetic profiles, enhancing treatment efficacy while minimizing side effects. Furthermore, advancements in imaging and surgical techniques have improved the detection and complete removal of tumors while preserving as much of the surrounding healthy tissue as possible. The integration of artificial intelligence in diagnostic processes also promises to enhance the accuracy and speed of breast cancer diagnostics, supporting early and reliable detection.

What Are the Emerging Trends in Breast Cancer Therapeutics?
Emerging trends in breast cancer therapeutics include a shift towards less invasive and more targeted treatment options. There is growing interest in the development of PARP inhibitors for treating triple-negative breast cancer, a subtype that does not respond to hormonal therapies. The use of CDK4/6 inhibitors in hormone receptor-positive breast cancer is another trend, offering new hope for patients with advanced cancer. Additionally, there is an increasing focus on developing therapies that provide not only longer survival but also better quality of life by reducing treatment-related side effects. The trend towards combination therapies, which use two or more drugs to attack cancer cells in different ways, is also gaining traction, offering new ways to overcome resistance to single-drug treatments.

What Drives the Growth of the Breast Cancer Therapeutics Market?
The growth in the breast cancer therapeutics market is driven by several factors, including the rising prevalence of breast cancer globally, which increases the demand for effective treatments. Advances in cancer research that lead to the discovery of novel drug targets and treatment regimens also contribute significantly to the expansion of the market. Furthermore, growing awareness and screening programs have led to earlier diagnosis, increasing the number of patients eligible for early-stage and potentially curative therapies. The expansion of healthcare coverage and increased healthcare spending globally enable greater access to these treatments, supporting market growth. Moreover, the strong pipeline of breast cancer drugs in clinical trials promises continuous improvement and expansion of treatment options, ensuring ongoing investment and interest in the sector. These dynamics underscore a market driven by both medical need and innovation, highlighting its critical importance in the field of oncology.

Select Competitors (Total 26 Featured) -
  • AstraZeneca PLC
  • Celgene Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer, Inc.
  • Roche Diagnostics
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Breast Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Advances in Oncology Research Propel Growth in Breast Cancer Therapeutics Market
Increasing Incidence of Breast Cancer Expands Addressable Market Opportunity
Technological Innovations in Targeted Therapies Generate Demand for Advanced Treatments
Growth in Personalized Medicine Drives Adoption of Breast Cancer Therapeutics
Rising Awareness and Early Detection Strengthens Business Case for Therapeutic Solutions
Adoption of Immunotherapies Spurs Growth in Breast Cancer Treatment
Impact of Genetic Testing and Biomarkers Expands the Market for Personalized Therapies
Demand for Minimally Invasive Treatments Generates Opportunities for Innovation
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Breast Cancer Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Breast Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 17: USA Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 18: USA Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: USA 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
CANADA
TABLE 20: Canada Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: Canada Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: Canada 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
JAPAN
Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 23: Japan Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: Japan Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: Japan 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
CHINA
Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 26: China Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: China Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: China 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
EUROPE
Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 29: Europe Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 30: Europe Historic Review for Breast Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Europe 16-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 32: Europe Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Europe Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Europe 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
FRANCE
Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 35: France Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: France Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: France 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
GERMANY
Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 38: Germany Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Germany Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Germany 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
ITALY
TABLE 41: Italy Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Italy Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Italy 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
UNITED KINGDOM
Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 44: UK Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: UK Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: UK 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
SPAIN
TABLE 47: Spain Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Spain Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Spain 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
RUSSIA
TABLE 50: Russia Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Russia Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Russia 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Rest of Europe Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Rest of Europe 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 57: Asia-Pacific Historic Review for Breast Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Asia-Pacific 16-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Asia-Pacific Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Asia-Pacific 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
AUSTRALIA
Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 62: Australia Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Australia Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Australia 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
INDIA
Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 65: India Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: India Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: India 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 68: South Korea Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: South Korea Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: South Korea 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Rest of Asia-Pacific Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Rest of Asia-Pacific 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
LATIN AMERICA
Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 74: Latin America Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 75: Latin America Historic Review for Breast Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Latin America 16-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 77: Latin America Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Latin America Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Latin America 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 80: Argentina Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Argentina Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Argentina 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
BRAZIL
TABLE 83: Brazil Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Brazil Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Brazil 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
MEXICO
TABLE 86: Mexico Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Mexico Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Mexico 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Rest of Latin America Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Rest of Latin America 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
MIDDLE EAST
Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 92: Middle East Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 93: Middle East Historic Review for Breast Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Middle East 16-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 95: Middle East Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Middle East Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Middle East 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
IRAN
TABLE 98: Iran Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Iran Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Iran 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
ISRAEL
TABLE 101: Israel Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Israel Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Israel 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Saudi Arabia Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Saudi Arabia 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 107: UAE Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: UAE Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: UAE 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Rest of Middle East Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Rest of Middle East 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
AFRICA
Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 113: Africa Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Africa Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Africa 16-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings